Deltex Medical Group PLC Result of AGM (0149S)

TIDMDEMG

RNS Number : 0149S

Deltex Medical Group PLC

20 June 2018

20 June 2018

Deltex Medical Group plc

Result of AGM

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), announces that all the resolutions proposed at today's AGM were duly passed.

Enquiries

 
 Deltex Medical Group 
  plc                          01243 774 837 
 Nigel Keen, Chairman           [e-mail] 
 Andy Mears, Chief 
  Executive 
 Jonathan Shaw, Group 
  Finance Director 
 
 Nominated Adviser 
  & Broker 
 Arden Partners plc            020 7614 5900 
 Chris Hardie 
 Ciaran Walsh 
 
 Joint Broker 
 Turner Pope Investments 
  (TPI) Ltd                     0203 621 4120 
 Andy Thacker                  [e-mail] 
 
 Financial Public Relations 
 IFC Advisory Ltd              0203 934 6630 
 Tim Metcalfe 
 Graham Herring 
 Heather Armstrong 
 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM (TrueVue(TM) Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue(TM) Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's TrueVue(TM) System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Group goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 40 countries.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGURVRRWKANUAR

(END) Dow Jones Newswires

June 20, 2018 07:01 ET (11:01 GMT)